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Antibodies to five PfEMP1 domains are differentially associated with age and infection 121 status 122
To investigate whether past and current exposure to malaria influence responses to the five 123 PfEMP1 domains, we investigated associations of antibody levels for each of the domains with 124 age and infection status respectively. Children were split into two groups on the basis of the 125 median age (1.7yrs) and median antibody responses were compared. Antibody levels were 126 significantly higher in the older children for group A but not group B/C domains ( Figure 2A) . 127 Therefore, the older children had more past exposure to group A antigens than younger children, 128 whereas group B/C domains were similarly recognized irrespective of age. Concurrent 129 microscopic parasitemia (median = 3349 parasites/uL) at the time of antibody measurement was 130 associated with significantly higher antibody levels as compared to the non-infected individuals 131 for all domains except group B NTS-DBL0.16PFL1955w (p = 0.94, Wilcoxon rank-sum test) 132 ( Figure 2B ), which was poorly reactive overall. Children who were infected at enrollment were 133 3.43 times more likely to be seropositive to at least one of the five PfEMP1 domains than non-134 infected children [Range: 1.6, 7.8, p = 0.002]. Therefore, current infection appears to boost 135 antibody levels for all antigens across the cohort. 136
Antibodies to DBLβ3PF11_0521 but not other domains are associated with reduced risk of high 137 density clinical malaria 138
To examine whether antibody responses against any of the domains were associated with 139 protection against clinical malaria, we conducted a prospective analysis of risk of febrile episodes 140 and antibody responses. Associations between plasma antibody levels and subsequent risk of 141 symptomatic malaria (all clinical episodes (fever and ≥2500 parasites/μl) and high density 142 clinical malaria (fever and ≥10000 parasites/μl)), were determined by grouping individuals into 143 tertiles, and comparing high and low antibody groups. An important feature of the analysis is the 144 adjustment for confounding variables at the individual level such as the molecular force of blood 145 stage infection (molFOB, see Materials and Methods). Children with high levels of antibodies to 146
DBLβ3PF11_0521 had a 37% reduction in risk of high-density clinical malaria that was highly 147 significant (febrile illness with ≥10000 parasites/μl: adjusted incidence rate ratio (aIRR) = 0.63 148 [95% CI: 0.45-0.88; p = 0.007]) and a 25% reduced risk of clinical malaria that was borderline 149 significant (febrile illness with ≥2500 parasites/μl: (aIRR) = 0.75 [95% CI: 0.55-1.01; p = 0.06]). 150 7 However, there was no significant reduction in risk in either presentation of clinical malaria for 151 the other four domains tested (Figure 3) . 152
Children that developed severe malaria had significantly lower antibodies to DBLβ3PF11_0521 153 Having determined that antibody responses to DBLβ3PF11_0521 were associated with protection 154 against clinical malaria, and in particular high-density clinical malaria, a biomarker for severe 155 disease, we then wanted to examine antibody responses in the children that experienced severe 156 disease in the follow-up period. According to WHO criteria (31), of the 187 children, 18 157 experienced severe P. falciparum malaria during the follow-up period ((25), Table S2 ). On 158 average, these children were similar to those that did not develop severe malaria with respect to 159 age (Severe cases: 1.64 yrs vs Non-severe cases: 1.89 yrs, p = 0.12) and exposure, experiencing a 160 similar number of distinct P. falciparum infections during the follow-up period (Severe: 5.19 and 161 non-severe: 5.17, p = 0.98). However, children who experienced severe malaria had significantly 162 lower antibodies to DBLβ3PF11_0521 at baseline than those that did not develop severe malaria 163 The PF11_0521 PfEMP1 variant is from 3D7, an isolate with possible African origin and dual-169 binding activity with ICAM1 (via DBL) and EPCR (via DC13, (21) (18, 19) ) were included in the analysis (Supporting File: Dataset 2). Of these, 22 contained 189 the ICAM1-binding motif and they were found within 11 DBL1 (50%) and 11 DBL3 (50%) 190 domains (Supporting File: Table S5 ). All DBL1 and 3 from both datasets (406 PNG + 178 191 other, Datasets 1 and 2) were then combined for multiple alignment. domains with no motif, p<0.0001, Binomial Exact Test) and DC4 (13.8% compared to 6.0%, 208 9 associated with severe malaria and dual EPCR/ICAM1-binding (21, 32). In the phylogenetic 210 analysis, DBL with adjacent DC4 and DC13 were divergent, although several DBLassociated 211 with DC4 were identical, suggesting conservation of a common var gene ( Figure S2 ). Other DC 212 structures including DC8, DC16 and DC1-var1 were not found amongst the PfEMP1 with the 213 ICAM1 binding motif ( Figure 5B ). This suggests that specific classes of PfEMP1 with dual 214 binding specificity to ICAM1 and EPCR are maintained in PNG isolates, confirming previous 215 10 DISCUSSION 217 218 PF11_0521 belongs to a class of group A PFEMP1 with DBL domains shown to bind ICAM1, 219 and found exclusively in PfEMP1 with EPCR-binding CIDR1 (16, 35) . These domains are 220 adjacent to each other and together they may produce a binding phenotype often associated with 221 sequestration leading to cerebral malaria (13, (18) (19) (20) (21) 32) . Our results support a role for these 222
PfEMP1 in clinical and severe malaria in young children by demonstrating that (i) antibodies 223 against DBLβ3PF11_0521 are significantly associated with protection against high-density clinical 224 malaria, (ii) children that developed severe malaria had lower levels of antibodies to 225 DBLβ3PF11_0521 prior to the disease episode (albeit antibodies to other antigens were also lacking 226 in these children), (iii) there are ICAM1-binding motifs present in DBL sequences from PNG 227 isolates, and (iv) PfEMP1/var genes with predicted ICAM1-binding are also predicted to bind 228
EPCR (21, 32). 229
The cohort of 1-3 year old PNG children was specifically chosen to explore early antibody 230 responses to PfEMP1, because their immunity to malaria was incomplete (25) and to limit the 231 complex background antibody responses that are observed in older children and adults (27) . 232
Antibodies to PfEMP1 domains were associated with age and current infection in the cohort, 233 consistent with exposure driving the acquisition and maintenance of immunity to malaria (2). In 234 addition to the measurement of exposure to new infections in the follow up period (molFOB), 235 these results provided a basis for exploring associations with the risk of disease adjusted for 236 important confounding factors (33). Because the number of severe disease cases was small 237 (n=18), we initially focused the prospective risk analysis on clinical infections, which occurred at 238 a high rate in these children (25). High density clinical malaria (fever plus ≥10,000 parasites/L) 239 is considered a surrogate marker for severe disease since these children have intense infections, 240 yet are not classified into any of the severe disease syndromes by WHO criteria (31). The 241 significant reduction in risk of these high density clinical infections if children had high levels of 242 DBLβ3PF11_0521 antibodies, suggests that inhibition of ICAM1-binding or other binding phenotype 243
by antibodies against these PfEMP1 may limit parasite burden and progression to severe malaria. 244
Antibodies to DBLβ3PF11_0521 have previously been associated with a reduced risk of 245 hospitalization with severe or moderately severe malaria in Tanzanian children (22) antibodies to merozoite antigens become biomarkers of protective immunity (33). We used the 279 molFOB as a marker of exposure at an individual level to adjust for the confounding effects of 280 exposure in the prospective risk analysis (26, 33). We observed significant protection against 281 clinical malaria in children with high levels of DBLβ3PF11_0521 antibodies despite these differing 282 exposures to malaria. That is, children who had antibodies to DBLβ3PF11_0521 had lower rates of 283 clinical malaria than those who had low levels of these antibodies, even after adjusting for 284 individual differences in the rate of new malaria infections. 285
We also found an association between the lack of antibodies to DBLβ3PF11_0521 and other group A 286
PfEMP1 domains and the prospective risk of severe malaria, however in this analysis we also 287 found associations with other antigens. Children who experienced only uncomplicated or 288 asymptomatic malaria had significantly higher levels of antibodies to all three group A antigens 289 and one of the group B antigens than children who developed severe malaria in the follow up 290 period. Taken together the observed association of antibodies to DBLβ3PF11_0521 with reduced 291 risk of high density clinical malaria and severe malaria suggests epitopes in DBLβ3PF11_0521-like 292 sequences or adjacent PfEMP1 domains may be important targets of protective immunity. 293
The association with other domains in severe malaria may be due to the fact that we did not 294 adjust for confounders and is also consistent with the early acquisition (and potential 295 protective effects) of antibody responses to group A antigens compared to B antigens 296 (27, 28, 30) . However, we cannot rule out that other domains tested are important targets of 297 protection against severe malaria. reactivity of children's sera to the full-length DBLβPF11_0521 supports the notion that conserved 314 epitopes exist that can be targeted by cross-reactive and protective antibodies (18, 21, 35) . 315
However, the ICAM1-binding motif is located in C-terminal part of the protein (SD3 region), 316
and no sequence traits in the N-terminal part of the domain have been linked to ICAM1 317 binding. The protective association may therefore be accounted for by epitopes outside the 318
SD3 region or as a result of its concurrence with other virulence-associated domains in the 319
same PfEMP1. 320
Our analysis of antibodies to functionally diverse PfEMP1 domains extends previous insights 321 into early exposure to PfEMP1 (22, 27, 28, 30) , revealing that young children from PNG are 322 highly exposed to group A antigens whilst having limited exposure to group B/C antigens. The 323 finding that high levels of antibodies against DBLβ3PF11_0521 are associated with a reduced risk of 324 high-density clinical and severe malaria supports a role for PfEMP1 in malaria pathogenesis via 325 ICAM1-binding domains or adhesion of adjacent domains. The demonstration that PNG P. NiNTA eluted CIDRα3.4PFL1955w and the refolded CIDRδPF13_0003 proteins were purified using 381 strong anion-exchange chromatography. Proteins were eluted from Hitrap Q column (GE 382 Healthcare) and the relevant fractions were pooled and concentrated. For CIDRα3.4PFL1955w, the 383 protein was further purified by size exclusion chromatography. The refolded NTS-384 DBL1.6PF13_0003 and NTS-DBLα0.16PFL1955w domains were further purified using cation-385 exchange chromatography. Bound proteins were eluted from a Hitrap SP column (GE 386 Healthcare) and the relevant fractions were pooled, concentrated and further purified by size 387 exclusion chromatography. The purity of each protein was assessed on SDS-PAGE gels and via 388 western immunoblots using standard conditions. Briefly, proteins were run on a 4-12% Bis-Tris 389 SDS-PAGE (Invitrogen). Standard Western blotting procedures were performed for non-reduced 390 and reduced (by addition of β-mercaptoethanol) samples using nitrocellulose and the 391 immunoblots were processed with enhanced chemiluminescence (ECL) substrates (GE 392 Healthcare). For all Western blots, recombinant proteins were detected with pooled hyperimmune 393 sera from highly exposed PNG adults (see Supplementary figure 1) . A single batch of each 394 protein was used for all serological screening. The purified proteins were assessed using a pool of 395 17 hyperimmune plasma (see Supplementary Figure 1 ) and a single batch of each protein was used 396 for all serological screening. 397
Measurement of antibody responses 398
Plasma samples collected at enrolment (n = 187) were tested for antibodies comprising total 399
Immunoglobulin G (IgG) to DBLβ3PF11_0521 using a standard ELISA assay. For the other four 400 domains, IgG levels were measured using the cytometric bead array (CBA) as described 401 previously (38). The details are described below. 402
ELISAs were performed to measure total IgG using standard methods. Ninety-six well plates 403 (Nunc, Denmark) were coated with 1μg/ml of DBLβ3PF11_0521 recombinant protein in PBS and 404 incubated overnight at 4°C. PBS with 5% skim milk was used for blocking and PBS with 1% 405 skim milk and 0.05% tween for diluting the plasma samples and antibodies. Plasma was added at 406 1 in 100 dilutions. For measurement of total IgG, horseradish peroxidase-conjugated mouse anti-407 human IgG (SouthernBiotech, USA) was used at a dilution of 1 in 1000. Finally, TMB microwell 408 peroxidase substrate (KPL, Inc., Australia) was added, and the reaction was stopped using 1M 409 H3PO4 and the optical density (OD) was measured at 450 nm. All samples were tested in 410 duplicate. Background (determined from the wells with no plasma) was deducted and the 411 threshold for a seropositive response was determined using reactivities of 1:100 diluted plasma 412 samples from anonymous malaria-naïve Australian adults (n=12). The mean value among these 413 negative control plasma samples plus 3SD was used as a cut-off value to define seropositivity. A serial dilution of plasma samples from a pool of hyperimmune PNG adults were included in 442 each plate to determine standard curves, which was later fitted using a 5-parameter logistic 443 regression model (Giraldo J, Vivas, NM et al. 2002 Pharmacol Ther) Table S3 ). Illumina® short read data sequences 470 were assembled using Velvet version 1.2.03 (39). Open reading frames were extracted using 471
Virtual Ribosome ORF finder (40) and var gene-encoded PfEMP1 domain sequences were 472 extracted from these by BLAST using a library of previously annotated PfEMP1 domain 473 sequences from 7 reference genomes and classified into subgroups as previously described (41). we then conducted a phylogenetic analysis using a total of 367 PNG DBLβ1 and DBL3 484 sequences originating from PNG isolates together with 89 DBLβ1 and DBL3 sequences from 485 the supplementary dataset. A maximum likelihood tree was estimated using the JTT substitution 486 model with 1000 bootstrap repetitions in MEGA version 7.0 (44). We measured the average 487 evolutionary divergence among sequences using the Dayhoff model in MEGA version 7.0 (44) . 488
In addition, we characterized the domain architecture of PfEMP1 with DBL1 and DBL3 489 domains by extracting the domain classifications from the BLAST output (Supporting File: Table  490 S6). We then assessed whether the frequency of each domain cassette amongst the ICAM1-motif 491 containing sequences varied significantly from the expected frequency (among a subset of 331 492
PfEMP1 with DBL1/3 domains) using an Exact Binomial test using R software (45). 493 show the interquartile range, midline is the median, whiskers the 95% confidence interval and 687 dots are the outliers (95-99%). P-values for the differences were determined using the Wilcoxon 688 rank-sum test between the groups. 689 Figure 3 . Antibody responses to five PfEMP1 domains and prospective risk of symptomatic 690 malaria. Antibody levels were grouped into three equal groups (High, Medium and Low). The 691 incidence rate of clinical malaria and high-density clinical malaria were compared for high and 692 low responders for each tested domain using negative binomial regression. The incidence rate 693 ratios were adjusted for villages of residence, seasonal variation, age (continuous), infection 694 status at the time of antibody measurement and differences in individual exposure (molFOB). 695
Adjusted incidence rate ratio (aIRR) for the comparison of high and low responders and the 95% 696 confidence intervals are shown. The p-values are indicated only when it is significant (p<0.05). 697 
